These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32463619)

  • 1. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.
    Siegel CA; Yang F; Eslava S; Cai Z
    Clin Transl Gastroenterol; 2020 Feb; 11(2):e00128. PubMed ID: 32463619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
    Brady JE; Stott-Miller M; Mu G; Perera S
    Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
    Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
    Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients.
    Rouiller-Braunschweig C; Fournier N; Pittet V; Dudler J; Michetti P
    Digestion; 2017 Nov; 96(4):220-227. PubMed ID: 29065423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
    Rubin DT; Mody R; Davis KL; Wang CC
    Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States.
    Gibble TH; Naegeli AN; Grabner M; Isenberg K; Shan M; Teng CC; Curtis JR
    BMC Gastroenterol; 2023 Mar; 23(1):63. PubMed ID: 36894911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
    Cai Q; Ding Z; Fu AZ; Patel AA
    BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication use among patients with Crohn's disease or ulcerative colitis before and after the initiation of advanced therapy.
    Hunter T; Naegeli AN; Nguyen C; Shan M; Smith JL; Tan H; Gottlieb K; Isenberg K
    BMC Gastroenterol; 2022 Nov; 22(1):474. PubMed ID: 36402945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
    Renna S; Cottone M; Orlando A
    World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
    Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
    J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns in Newly Diagnosed Patients with Crohn's Disease Who Received Biologics Following Diagnosis: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Medical Claims Database in Japan.
    Hirai F; Uda A; Ota M; Takemura Y; Tanaka K; Iwakiri R
    Digestion; 2023; 104(2):109-120. PubMed ID: 36450239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
    Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
    BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Biologic Treatment Decreases Risk of Surgery in Crohn's Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis.
    Law CCY; Tkachuk B; Lieto S; Narula N; Walsh S; Colombel JF; Ungaro RC
    Inflamm Bowel Dis; 2024 Jul; 30(7):1080-1086. PubMed ID: 37506265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study.
    Glassner K; Oglat A; Duran A; Koduru P; Perry C; Wilhite A; Abraham BP
    J Dig Dis; 2020 May; 21(5):264-271. PubMed ID: 32324969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration.
    Wang Y; Makadia R; Knoll C; Hardin J; Voss EA; Fife D; Davis K; Sloan S
    BMC Gastroenterol; 2021 Mar; 21(1):121. PubMed ID: 33731009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.